Annovis Bio announces first patients entered Phase 3 study of buntanetap
Annovis Bio (ANVS) announced that the first two patients have been entered into the Phase 3 study evaluating buntanetap in early AD. “The launch of our highly anticipated AD study is a significant ...
Insiders Pull the Trigger on 2 Dividend Stocks With Double-Digit Upside
Finding the best stocks for your investment portfolio isn’t about mastering some hidden trick – it’s about understanding the ...
Goldman Sachs Doubles Palantir (PLTR) Stock’s Price Target but Keeps a Hold Rating
Big data analytics company Palantir Technologies (PLTR) saw its price target double to $80 from $41 by Goldman Sachs analyst Gabriela Borges.
Hosted on MSN11h
ResMed Inc Director Plans Sale of 2,000 Shares
An announcement from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ) is now available. ResMed Inc has ...
Hosted on MSN11h
‘DeepSeek Is a Big Threat,’ Says Top Analyst About Nvidia Stock
Nvidia (NASDAQ:NVDA) shares had a nice rally today, surging nearly 5%. Yet, the stock hasn’t fully recovered from the recent ...
‘Dump Now, Buy Later,’ Says Investor About Tesla Stock
Tesla (NASDAQ:TSLA) isn’t just building cars – it’s selling a vision of the future. And to invest in it, you need to buy into ...